Pharmacologic Treatment and Management of Coronavirus Disease 2019.
| Autor: | Shumaker AH; Clinical Pharmacy Specialist-Infectious Disease, Department of Pharmacy, VA Northeast Ohio Healthcare System, 10701 East Boulevard, Pharmacy 119 (W), Cleveland, OH 44106, USA; Senior Clinical Instructor, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-7341. Electronic address: amy.hirsch@va.gov., Bhimraj A; Section Head Neurologic Infectious Diseases, Department of Infectious Diseases, Cleveland Clinic, 9500 Euclid Avenue/g21, Cleveland, OH 44195, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Infectious disease clinics of North America [Infect Dis Clin North Am] 2022 Jun; Vol. 36 (2), pp. 349-364. Date of Electronic Publication: 2022 Feb 10. |
| DOI: | 10.1016/j.idc.2022.02.001 |
| Abstrakt: | Over the last 2 years, there has been gradual and sustained progress toward our understanding of pharmacotherapy for coronavirus disease 2019 (COVID-19) as a result of large- and small-scale randomized controlled trials. Numerous new and repurposed treatments have been evaluated; some have demonstrated benefit in clinically important outcomes like mortality and hospitalization, and optimism for oral antiviral treatments is growing. Given the rapidly evolving landscape of COVID-19 treatments, frontline clinicians should use treatment and management guidelines to guide their approach to each patient, with the individual's severity and location of illness in mind to appreciate the nuances in clinical evidence. (Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|